Last reviewed 2026-04-20 · How we verify

fluorine F 18 fluorothymidine

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Neutropenia
• Myalgia
• Neutrophil count decreased
• Platelet count decreased
• White blood cell decreased
• Alanine aminotransferase increased
• Anemia
• Constipation
• Fatigue
• Anorexia
• Fever

Key clinical trials

• FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia (PHASE2)
• Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 (PHASE1)
• Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy (EARLY_PHASE1)
• Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement (PHASE2)
• Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma (PHASE1)
• SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients (PHASE1, PHASE2)
• Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer (PHASE1)
• [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• fluorine F 18 fluorothymidine CI brief — competitive landscape report
• fluorine F 18 fluorothymidine updates RSS · CI watch RSS
• Mayo Clinic portfolio CI